Inspiration Biopharmaceuticals names John Butler as ceo

Replaces Michael Griffith who takes position of cso

Inspiration Biopharmaceuticals, a US biopharmaceutical company focused on the development of treatments haemophilia, has appointed John Butler as ceo. He has replaced Michael Griffith, who has become chief scientific officer and remains company president.

Butler has joined Inspiration from Genzyme, which was acquired by Sanofi in April. While at Genzyme, he was most recently president of the company's rare genetic diseases business. He also led the company's renal, endocrinology, and cardiovascular businesses.

Prior to Genzyme, Butler held sales and marketing positions at Amgen and Hoffmann-La Roche.

You may also like

Manufacturing

CMC Biologics and Inspiration agree supply of IB1001

For the treatment and prevention of bleeding in haemophilia B patients
Regulatory

AstraZeneca's New Drug Application for hypertension drug accepted under FDA Priority Review

Baxdrostat has had positive Phase III trial results and, if approved, could be the first aldosterone synthase inhibitor to receive regulatory authorisation
Pharmaceutical

Samsung Bioepis expands European biosimilar portfolio with OBODENCE and XBRYK launches

The products, targeting osteoporosis and bone-related complications in cancer, strengthen access to affordable care and expand the company’s direct sales footprint across endocrinology and oncology
Regulatory

EU approves Sanofi and Regeneron’s Dupixent as first targeted CSU treatment in more than a decade

The European Commission has authorised Dupixent for moderate-to-severe chronic spontaneous urticaria in patients aged 12+, offering the first new targeted option in more than ten years
Regulatory

FDA grants Medivir’s MIV-711 Orphan Drug Designation for Osteogenesis Imperfecta treatment

The FDA has awarded Orphan Drug Designation to Medivir’s selective cathepsin K inhibitor MIV-711 for Osteogenesis Imperfecta, a rare genetic bone disorder, after preclinical and clinical data suggests the therapy may strengthen bone
Sustainability

Solvent recyclers improve HPLC system sustainability

A leading pharmaceutical company has purchased 17 SPR-200 solvent recycler units from Biotech Fluidics improving sustainable use of solvents by HPLC systems in their analytical laboratories
Pharmaceutical

Polpharma Biologics announces US launch of Tyruko, the first FDA-approved natalizumab biosimilar for MS

Tyruko is now available to US patients with multiple sclerosis and Crohn’s disease, expanding access to a more affordable biologic option
Subscribe now